FOLD ( update ) Pompe program was set back by FDA refusal to grant accelerated review status More clinical data is due in the Pompe program during Q4/18 Commercial efforts for the Fabry program are going reasonably well and they raised revenue guidance for the rest of the year. Cash runway is at least thru 2020; but, FOLD has a history of raising capital whenever they can.